Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis
Crossref DOI link: https://doi.org/10.1007/s40268-017-0210-z
Published Online: 2017-09-13
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pandey, Richa
Zella, Julia B.
Zhu, Jinge G.
Plum, Lori A.
Clagett-Dame, Margaret
Blaser, William J.
Bedale, Wendy
DeLuca, Hector F.
Coyne, Daniel W.
Funding for this research was provided by:
Deltanoid Pharmaceuticals, Inc.
License valid from 2017-09-13